By interfering with the PP2A-mediated dephosphorylation, SET activates oncogenic signaling such as AKT, ERK, c-MYC and GSK3-β to promote the survival and proliferation of cancer cells [18,19]. The gene discussed is AKT1; the disease is cancer.